title: Benefit of converting enzyme inhibition on left ventricular volumes and ejection fraction in patients receiving beta-blockade after myocardial infarction. CONSENSUS II multiecho study group.
abstract: Beta-blockers reduce infarct size and improve survival after acute myocardial infarction (MI). Post-MI angiotensin-converting enzyme inhibition also improves survival and may attenuate left ventricular (LV) dilatation. We evaluated the effect of early enalapril treatment on LV volumes and ejection fraction (EF) in patients on concomitant beta-blockade after MI. Intravenous enalaprilat or placebo was administered <24 hours after MI and was continued orally for 6 months. LV volumes were assessed by echocardiography 3 +/- 2 days, 1 and 6 months after MI. Change in LV diastolic volume during the first month was attenuated with enalapril (2.7 vs placebo 6.5 ml/m2 change; p < 0.05), and significantly lower LV diastolic and systolic volumes were observed with enalapril treatment compared with placebo at 1 month (enalapril 47.21 23.9 vs placebo 53.1/29.2 ml/m2; p < 0.05) and at 6 months (enalapril 47.9/24.8 vs placebo 53.8/29.6 ml/m2; p < 0.05). EF was also significantly higher 1 month after MI in these patients (enalapril 50.4% vs placebo 46.4%; p < 0.05). Our date demonstrate that early enalapril treatment attenuates LV volume expansion and maintains lower LV volumes and higher EF in patients receiving concurrent beta-blockade after MI. A possible additive effect of combined therapy should be evaluated prospectively.
authors.affiliation: Cardiology Division, Department of Medicine, Central Hospital in Rogaland, Stavanger, Norway.
authors.forename: V V
authors.initials: VV
authors.lastname: Bonarjee
authors.forename: S
authors.initials: S
authors.lastname: Carstensen
authors.forename: K
authors.initials: K
authors.lastname: Caidahl
authors.forename: D W
authors.initials: DW
authors.lastname: Nilsen
authors.forename: M
authors.initials: M
authors.lastname: Edner
authors.forename: K
authors.initials: K
authors.lastname: Lindvall
authors.forename: S M
authors.initials: SM
authors.lastname: Snapinn
authors.forename: J
authors.initials: J
authors.lastname: Berning
mesh_terms: D000284:Administration, Oral; D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D002306:Cardiac Volume / Q000187:drug effects*; D003971:Diastole; D004108:Dilatation, Pathologic / Q000517:prevention & control; D004311:Double-Blind Method; D004656:Enalapril / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006331:Heart Diseases / Q000517:prevention & control; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D009203:Myocardial Infarction / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D010919:Placebos; D011446:Prospective Studies; D013318:Stroke Volume / Q000187:drug effects*; D015996:Survival Rate; D013599:Systole; D016277:Ventricular Function, Left / Q000187:drug effects*
chemical_list: D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D010919:Placebos; D004656:Enalapril